Dirucotide

Summary

Dirucotide (CHEMBL2105639) is a phase-3 clinical-stage protein; indicated across 3 conditions including chronic progressive multiple sclerosis and secondary progressive multiple sclerosis.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Protein
• Indications: 3 conditions
• Clinical trials: 4
• Chemistry: 2013.3 Da · C92H141N25O26

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2105639
Name	Dirucotide
Type	Protein
Max phase	3
FDA approved	no
PubChem CID	70683017
Molecular formula	C92H141N25O26
Molecular weight	2013.3
InChIKey	RCTCWZRPYFBGLQ-KVBIMOIYSA-N

SMILES: CC[C@H](C)[C@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC4=CN=CN4)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]5CCCN5C(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(=O)O)N

IUPAC name: (4S)-5-[[(2S)-4-amino-1-[(2S)-2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-4-amino-1-[[(2R,3S)-1-[[(2S)-1-[[(2S,3R)-1-[(2S)-2-[[(2S)-5-carbamimidamido-1-[[(1S,2R)-1-carboxy-2-hydroxypropyl]amino]-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-3-hydroxy-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]carbamoyl]pyrrolidin-1-yl]-1,4-dioxobutan-2-yl]amino]-4-[[(2S)-2-amino-3-carboxypropanoyl]amino]-5-oxopentanoic acid

Also known as: Dirucotida, Dirucotide, MBP-8298, MBP8298, MBP8298 PEPTIDE, SF328, DIRUCOTIDE

Parent form; salt/anhydrous children: CHEMBL2105640

Patent coverage: 104 distinct patent families (315 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

3 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
chronic progressive multiple sclerosis	3	MONDO:0005284	EFO:0003840
secondary progressive multiple sclerosis	3	MONDO:0000450	EFO:0008522
relapsing-remitting multiple sclerosis	2	MONDO:0005314	EFO:0003929

Clinical trials

Total trials: 4.

Phase distribution

Phase	Trials
PHASE2/PHASE3	3
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00468611	PHASE3	TERMINATED	Efficacy and Safety of MBP8298 in Subjects With Secondary Progressive Multiple Sclerosis
NCT00869726	PHASE2/PHASE3	COMPLETED	A Study for Patients With Secondary Progressive Multiple Sclerosis
NCT00869986	PHASE2/PHASE3	COMPLETED	A Study for Patients With Relapsing Remitting Multiple Sclerosis
NCT00870155	PHASE2/PHASE3	TERMINATED	A Study for Patients With Multiple Sclerosis

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).